Ideaya Biosciences Inc (IDYA)

$22.39 +0.21 (0.95%)
Market Cap 1.94B
Revenue (ttm) 7.00M
Net Income (ttm) -274.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,921.14%
Debt to Equity Ratio 0.00
Volume 838,400
Avg Vol 1,477,024
Day's Range N/A - N/A
Shares Out 87.58M
Stochastic %K 73%
Beta 0.04
Analysts Strong Sell
Price Target $51.23

Company Profile

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumor...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 443 6209
Address:
5000 Shoreline Court, Suite 300, South San Francisco, United States
himsssss
himsssss Jun. 13 at 3:49 PM
$IDYA todays dip was a nice gift on starting a position.
0 · Reply
himsssss
himsssss Jun. 12 at 8:46 PM
$IDYA Eyeing for a position tmrw. Liking the news ahead of us.
0 · Reply
WSRX
WSRX Jun. 12 at 8:36 PM
$IDYA I’m actually starting to think the DLL3 update by Hengrui (IDYA has WW rights and I licensed from them) in Q3 may end up being a bigger catalyst than many expect. I fully expect it to be better and safer than ZLAB’s DLL3, and they’ve had quite the jump since their ASCO update.
0 · Reply
topstockalerts
topstockalerts Jun. 10 at 6:24 PM
$IDYA making a solid move..👀👀..
0 · Reply
CDMO
CDMO Jun. 10 at 6:00 PM
$IDYA
0 · Reply
CH_Expat
CH_Expat Jun. 10 at 5:55 PM
$IDYA CEO was good at Goldman Facks conference. Relaxed and humble. Liked his performance.
1 · Reply
RonIsWrong
RonIsWrong Jun. 10 at 1:54 PM
$IDYA going the right way.
0 · Reply
CH_Expat
CH_Expat Jun. 10 at 8:41 AM
$ARWR Avg 15 $IDYA Avg 19 $GMAB Avg 20 $SNDX Avg 11 Was looking for other great value options in bios on the weekend, not finding any better ones. Will add to those four on corrections first before I consider to open new positions.
0 · Reply
RonIsWrong
RonIsWrong Jun. 9 at 8:29 PM
$IDYA Point72 Capital Advisors, Inc. buys 4,412,432 shares
0 · Reply
RonIsWrong
RonIsWrong Jun. 4 at 5:07 PM
$IDYA higher high. so far so good.
0 · Reply
Latest News on IDYA
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events

Jun 2, 2025, 6:00 AM EDT - 14 days ago

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 30, 2025, 6:00 AM EDT - 17 days ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849

May 14, 2025, 5:30 PM EDT - 4 weeks ago

Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 6:05 AM EDT - 5 weeks ago

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

May 6, 2025, 6:00 AM EDT - 5 weeks ago

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

Apr 28, 2025, 6:00 AM EDT - 7 weeks ago

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

Apr 16, 2025, 8:52 AM EDT - 2 months ago

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

Apr 14, 2025, 6:00 AM EDT - 2 months ago

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

Apr 10, 2025, 6:00 AM EDT - 2 months ago

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

Why Ideaya Biosciences Is Down Despite Many Positives

Apr 2, 2025, 11:12 AM EDT - 2 months ago

Why Ideaya Biosciences Is Down Despite Many Positives

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events

Apr 1, 2025, 6:00 AM EDT - 2 months ago

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

Mar 31, 2025, 6:00 AM EDT - 2 months ago

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor

Mar 26, 2025, 6:00 AM EDT - 2 months ago

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

Mar 3, 2025, 6:00 AM EST - 3 months ago

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 13, 2025, 6:05 AM EST - 4 months ago

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

Feb 13, 2025, 6:00 AM EST - 4 months ago

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming

Feb 10, 2025, 4:36 PM EST - 4 months ago

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

Feb 10, 2025, 6:00 AM EST - 4 months ago

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

Jan 27, 2025, 6:00 AM EST - 5 months ago

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

Jan 12, 2025, 12:00 PM EST - 5 months ago

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

Dec 29, 2024, 6:00 AM EST - 6 months ago

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

Dec 17, 2024, 6:00 AM EST - 6 months ago

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

Dec 16, 2024, 6:00 AM EST - 6 months ago

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

Dec 11, 2024, 6:00 AM EST - 6 months ago

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

Dec 10, 2024, 6:00 AM EST - 6 months ago

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

Dec 9, 2024, 6:00 AM EST - 6 months ago

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Dec 4, 2024, 2:00 PM EST - 6 months ago

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

Dec 2, 2024, 6:00 AM EST - 7 months ago

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

Nov 18, 2024, 6:00 AM EST - 7 months ago

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day

Nov 12, 2024, 6:00 AM EST - 7 months ago

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen

Nov 11, 2024, 6:00 AM EST - 7 months ago

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen

Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

Nov 11, 2024, 6:00 AM EST - 7 months ago

Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 6:00 AM EST - 8 months ago

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

Oct 28, 2024, 6:00 AM EDT - 8 months ago

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

Oct 25, 2024, 6:00 AM EDT - 8 months ago

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

Oct 4, 2024, 6:00 AM EDT - 9 months ago

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate

Sep 23, 2024, 10:07 AM EDT - 9 months ago

Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

Sep 23, 2024, 6:00 AM EDT - 9 months ago

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

Sep 22, 2024, 9:00 AM EDT - 9 months ago

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

Sep 20, 2024, 12:45 PM EDT - 9 months ago

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

Sep 18, 2024, 6:00 AM EDT - 9 months ago

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 6:00 AM EDT - 10 months ago

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 6:00 AM EDT - 11 months ago

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Generational Group Advises Schuylkill Haven Casket Company and Columbia Caskets Corp. in its sale to Victoriaville & Co.

Jul 31, 2024, 4:48 PM EDT - 11 months ago

Generational Group Advises Schuylkill Haven Casket Company and Columbia Caskets Corp. in its sale to Victoriaville & Co.

FNA

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Jul 31, 2024, 6:00 AM EDT - 11 months ago

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

Jul 31, 2024, 6:00 AM EDT - 11 months ago

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

Jul 29, 2024, 6:00 AM EDT - 11 months ago

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 11, 2024, 4:05 PM EDT - 1 year ago

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Announces Pricing of Public Offering

Jul 9, 2024, 10:26 PM EDT - 1 year ago

IDEAYA Announces Pricing of Public Offering

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jul 9, 2024, 4:08 PM EDT - 1 year ago

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

himsssss
himsssss Jun. 13 at 3:49 PM
$IDYA todays dip was a nice gift on starting a position.
0 · Reply
himsssss
himsssss Jun. 12 at 8:46 PM
$IDYA Eyeing for a position tmrw. Liking the news ahead of us.
0 · Reply
WSRX
WSRX Jun. 12 at 8:36 PM
$IDYA I’m actually starting to think the DLL3 update by Hengrui (IDYA has WW rights and I licensed from them) in Q3 may end up being a bigger catalyst than many expect. I fully expect it to be better and safer than ZLAB’s DLL3, and they’ve had quite the jump since their ASCO update.
0 · Reply
topstockalerts
topstockalerts Jun. 10 at 6:24 PM
$IDYA making a solid move..👀👀..
0 · Reply
CDMO
CDMO Jun. 10 at 6:00 PM
$IDYA
0 · Reply
CH_Expat
CH_Expat Jun. 10 at 5:55 PM
$IDYA CEO was good at Goldman Facks conference. Relaxed and humble. Liked his performance.
1 · Reply
RonIsWrong
RonIsWrong Jun. 10 at 1:54 PM
$IDYA going the right way.
0 · Reply
CH_Expat
CH_Expat Jun. 10 at 8:41 AM
$ARWR Avg 15 $IDYA Avg 19 $GMAB Avg 20 $SNDX Avg 11 Was looking for other great value options in bios on the weekend, not finding any better ones. Will add to those four on corrections first before I consider to open new positions.
0 · Reply
RonIsWrong
RonIsWrong Jun. 9 at 8:29 PM
$IDYA Point72 Capital Advisors, Inc. buys 4,412,432 shares
0 · Reply
RonIsWrong
RonIsWrong Jun. 4 at 5:07 PM
$IDYA higher high. so far so good.
0 · Reply
WSRX
WSRX Jun. 4 at 12:33 AM
$IDYA darovasertib works - and as we’ve heard from management, some vision is even coming back for patients which is unheard of
1 · Reply
CH_Expat
CH_Expat Jun. 3 at 6:47 AM
$IDYA Big pharma finally going M&A on firesale prices that get accepted. This is definately a candidate. Unfortuately companies go too cheap, so I would expect 3.5b.
2 · Reply
RonIsWrong
RonIsWrong May. 28 at 3:04 PM
$IDYA doing well let's see if it can push to a higher high now.
0 · Reply
CDMO
CDMO May. 27 at 7:44 PM
$IDYA looking good i d say
0 · Reply
WSRX
WSRX May. 23 at 3:57 PM
$IDYA added more today. Up to 9k shares here now
2 · Reply
WSRX
WSRX May. 21 at 6:05 PM
$IDYA bought some more today
1 · Reply
CDMO
CDMO May. 20 at 7:52 PM
$IDYA beautiful
0 · Reply
RonIsWrong
RonIsWrong May. 20 at 5:51 PM
$IDYA support held
1 · Reply
CH_Expat
CH_Expat May. 20 at 2:10 PM
$IDYA $GMAB $ARWR Where will I add?
2 · Reply
DHolliday
DHolliday May. 13 at 2:49 PM
How it feels checking the portfolio as a Tech/Bio investor lately $IDYA $SNDX $TARS
0 · Reply
RonIsWrong
RonIsWrong May. 13 at 2:34 AM
$IDYA let's see now..
0 · Reply
WSRX
WSRX May. 12 at 7:49 PM
$IDYA up to 7,000 shares now
0 · Reply